A new study published in JAMA Ophthalmology suggests that GLP-1 medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), could be linked to a rare but serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). While these drugs are effective for weight loss, the study warns of potential irreversible vision loss. Patients experiencing any changes in vision while taking these medications should consult their doctor immediately.
Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle. Subscribe to Best Life's newsletter now.Our content is fact checked by our senior editorial staff to reflect accuracy and ensure our readers get sound information and advice to make the smartest, healthiest choices.
JAMA Ophthalmology: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutideand Wegovy that we know constipation, bloating, heartburn, and gastrointestinal discomfort aren't out of the ordinary. However, now that semaglutide injections are becoming more mainstream, lesser-known complications of the drugs are coming to light. In fact, a new study says GLP-1 medications could cause patients to permanently lose their vision.
According to Katz, a disruption in eye vision can be caused by a number of variables. But in terms of GLP-1 medications, fluctuating blood sugar levels are likely to blame. “What we are recommending is that if you experience a change in your vision while using one of these drugs, you should consult the prescribing doctor and see an ophthalmologist,” said Katz.
GLP-1 Medications Semaglutide Tirzepatide NAION Vision Loss Eye Health
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'Weight loss is misunderstood': New health and weight loss shake taking Utah by stormJoel Bikman and his scientist brother, the co-founders of an innovative new health and weight loss company, are using the latest science to help set the record straight to help people get much healthier.
Read more »
New Weight Loss Drugs May Fight Obesity-Related Cancer, TooCancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Read more »
Ozempic and Other Weight-Loss Drugs Linked to Organ Damage Risk: StudyA new study analyzing medical records of over 2 million veterans found a possible association between popular GLP-1 drugs like Ozempic and an increased risk of damage to the kidneys, pancreas, and digestive system. While these drugs offer benefits for weight management and diabetes treatment, the study highlights the need for further research to fully understand their long-term effects.
Read more »
Eli Lilly Cuts 2024 Revenue Forecast Amid Softer Demand for Weight Loss and Diabetes DrugsEli Lilly, a leading pharmaceutical company, reduced its 2024 revenue outlook due to lower-than-expected sales for its weight loss and diabetes medications. The company now predicts annual revenue of around $45 billion, down from its previous estimate. This downgrade reflects the slower-than-anticipated growth of incretin drugs, a class that includes Mounjaro and Zepbound, which are key products for Eli Lilly.
Read more »
GLP-1 Drugs: A Weight Loss Solution or Overused Remedy?With rising obesity rates, GLP-1 drugs like Ozempic and Wegovy have gained popularity for weight loss. While effective, concerns remain about potential long-term health risks and overuse. This article explores the benefits and drawbacks of these drugs compared to traditional lifestyle changes.
Read more »
Eli Lilly Cuts 2024 Revenue Guidance as Demand for Weight Loss and Diabetes Drugs SlowsEli Lilly & Co., a leading pharmaceutical company, has lowered its 2024 revenue expectations due to slower-than-anticipated growth in demand for its obesity and diabetes medications. The company attributes the revised forecast to factors such as market growth not meeting initial projections and lower-than-expected channel inventory levels at year-end.
Read more »